[Therapeutic efficacy of locobase cream in the treatment of atopic dermatitis].
Moisturizing and softening therapeutic dermatological-cosmetic external pharmacological agents are fundamental to the rehabilitation of children and adults with AD; they are also included in the care process of dry and sensitive skin. The above requirements are met by a new drug of the Netherlands firm "Astellas" lokobeyz. The aim of this presentation was: to study clinical efficacy and safety of the cream lokobeyz in patients with AD. The study included 25 patients with AD, suffering from mild and moderate forms of AD (11 male and 14 female persons, aged 2 to 18 years, with the prescription of the disease from 1 to 10 years). Cream lokobeyz in the form of monotherapy received 25 patients, which they applied themselves to the lesions with a thin layer 2 times a day, morning and evening until the full resolution of the process. Clinical effectiveness was evaluated on the 7th and 14th day after the start of therapy. Efficacy and tolerability of the drug was evaluated by the following criteria: in the patients with AD by the SCORAD scale - by the presence of side effects, complications and tolerability. Clinical effectiveness of treatment of patients, conducted on the 7th and 14th - days was 90% (22 of 25 patients). The therapeutic effect was already revealed in 7-10 days. Thus, the cream lokobeyz possesses a strong moisturizing and keratoplastic properties is convenient to use, well tolerated and has high clinical efficacy. Thus, it may be recommended as the drug of choice in treatment of allergic dermatsis, accompanied by dryness of the skin.